Xiao Gary Guishan, Recker Robert R, Deng Hong-Wen
Osteoporosis Research Center, Departments of Medicine and Biomedical Sciences, Creighton University, 601 N 30 ST, Suite 6730, Omaha, NE 68131.
Clin Med Oncol. 2008;2:63-72. doi: 10.4137/cmo.s539. Epub 2008 Feb 9.
Early diagnosis and prevention is a key factor in reducing the mortality and morbidity of cancer. However, currently available screening tools lack enough sensitivity for early diagnosis. It is important to develop noninvasive techniques and methods that can screen and identify asymptomatic patients who have cancer. Biomarkers of cancer status can also serve as powerful tools in monitoring the course of cancer and in determining the efficacy and safety of novel therapies. Thus, discovery of novel specific biomarkers are needed that may provide informative clues for early diagnosis and treatment of cancer. Recently, remarkable progress has been made in the development of new proteomics technology. The progress that has been made in this field is helpful in identifying biomarkers that can be used for early diagnosis of cancer and improving the understanding of the molecular etiological mechanism of cancer. This article describes the current state of the art in this field.
早期诊断和预防是降低癌症死亡率和发病率的关键因素。然而,目前可用的筛查工具对早期诊断缺乏足够的敏感性。开发能够筛查和识别无症状癌症患者的非侵入性技术和方法非常重要。癌症状态的生物标志物也可作为监测癌症进程以及确定新疗法疗效和安全性的有力工具。因此,需要发现新的特异性生物标志物,为癌症的早期诊断和治疗提供有用线索。最近,新的蛋白质组学技术开发取得了显著进展。该领域取得的进展有助于识别可用于癌症早期诊断的生物标志物,并增进对癌症分子病因机制的理解。本文介绍了该领域的当前技术水平。